In-vivo Bioequivalence Study of Levodopa/Benserazide 125 mg HBS Capsules and Dispersible Tablets of The Test Drug (Norstor® 125 mg HBS Capsules and Dispersible Tablets, Pars Gita Darou, Iran)
Not Applicable
Recruiting
- Conditions
- This study is performed on healthy volunteers and drug concentration in plasma is determined..
- Registration Number
- IRCT20200105046010N110
- Lead Sponsor
- Pars Gita Daru
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (Liver, Heart, and Kidney)
Body Mass Index (18-28) kg/m^2
Informed consent
Age (18-55 years old)
Exclusion Criteria
Smoking
History of cardiovascular disease
History of liver and kidney disease
Alcohol and drug addiction
History of allergy to Levodopa/Benserazide
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Levodopa/Benserazide in plasma concentration modulation for Parkinson's disease?
How does Norstor® compare to Madopar® in terms of bioavailability and therapeutic efficacy in healthy volunteers?
Are there specific biomarkers that correlate with Levodopa absorption rates in Iranian populations?
What adverse events are associated with Levodopa/Benserazide formulations and how are they managed clinically?
What is the role of Benserazide in enhancing Levodopa bioequivalence in dispersible tablet versus capsule forms?